Test Assists Risk Assessment/Early Detection of Lung Cancer

The test detects the body’s immune response, in the form of autoantibodies (or immuno-biomarkers), to antigens produced by solid-tumor cells.

A panel of tumor antigens is selected for their involvement in the development of lung cancer. Autoantibodies form and circulate in the body at all stages of the disease including Stages I and IIA, which are the earliest stages of lung cancer. Their measurement may signify the presence of cancerous cells.

Early CDT-Lung has been approved by the New York State Department of Health. Utilizing a simple blood specimen, the test is directed at patients with a high risk of developing lung cancer, including heavy smokers, those exposed to suspect environmental conditions, and patients with a CT nodule under surveillance.

The availability of EarlyCDT-Lung by Enzo Clinical Labs (New York, NY, USA) is the result of an agreement with its developer, Kansas-based Oncimmune (De Soto, KS, USA). The agreement provides for Enzo to be the only clinical laboratory located within its marketing area to make the test available to physicians.

The new diagnostic test that assists in risk assessment and early detection of lung cancer is being made available to physicians in the New York metropolitan market as well as New Jersey and Eastern Pennsylvania. Enzo is the only clinical laboratory making the test available in those areas.

Enzo Clinical Labs is a full service clinical reference laboratory. The company combines the extensive testing capabilities of a large laboratory with the convenience and personalized service of a local one. Enzo was one of the area's first laboratories to be awarded the College of American Pathologists (CAP) accreditation. This award indicates that Enzo passed a rigorous series of inspections more sophisticated than those mandated by licensing authorities.


Related Links:
Enzo Clinical Labs
Oncimmune